Reply to Albulushi et al.-Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From RHAPSODY Long-term Extension.
作者信息
Brucato Antonio, Klein Allan L, Imazio Massimo, Paolini John F
出版信息
CJC Open. 2024 Jun 15;6(8):1033-1034. doi: 10.1016/j.cjco.2024.05.014. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Reply to Albulushi et al.-Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From RHAPSODY Long-term Extension.对阿尔布卢希等人的回复——接受利罗那肽治疗的COVID-19患者和接种SARS-CoV-2疫苗后心包炎未复发：RHAPSODY长期扩展研究结果
CJC Open. 2024 Jun 15;6(8):1033-1034. doi: 10.1016/j.cjco.2024.05.014. eCollection 2024 Aug.
2
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension.接受利罗那肽治疗的 COVID-19 患者和接种 SARS-CoV-2 疫苗后心包炎未复发：RHAPSODY 长期扩展研究结果
CJC Open. 2024 Mar 4;6(6):805-810. doi: 10.1016/j.cjco.2024.02.002. eCollection 2024 Jun.
3
Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.长期用利纳西普降低持续性心包炎复发风险。
J Am Heart Assoc. 2024 Mar 19;13(6):e032516. doi: 10.1161/JAHA.123.032516. Epub 2024 Mar 12.
4
Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis.在对利罗那肽产生临床反应后以及治疗中断复发前进行的纵向心脏磁共振成像：一项RHAPSODY亚组分析。
Eur Heart J Cardiovasc Imaging. 2024 Dec 31;26(1):72-79. doi: 10.1093/ehjci/jeae200.
5
Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis.心包晚期钆增强与复发时间：来自RHAPSODY的一项亚研究，rilonacept治疗复发性心包炎的3期临床试验
Eur Heart J Imaging Methods Pract. 2023 May 26;1(1):qyad003. doi: 10.1093/ehjimp/qyad003. eCollection 2023 May.
6
Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY.白细胞介素-1 陷阱利纳西普在复发性心包炎患者中改善健康相关生活质量和睡眠：来自 3 期临床试验 RHAPSODY 的结果。
J Am Heart Assoc. 2022 Oct 18;11(20):e023252. doi: 10.1161/JAHA.121.023252. Epub 2022 Oct 17.
7
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.从口服药物转换为利那洛肽单药治疗复发性心包炎患者。
Heart. 2023 Jan 27;109(4):297-304. doi: 10.1136/heartjnl-2022-321328.
8
RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.RHAPSODY：评估重组人白细胞介素-1受体拮抗剂（IL-1α/IL-1β Trap）治疗复发性心包炎的疗效和安全性的关键性 3 期临床试验的原理和设计。
Am Heart J. 2020 Oct;228:81-90. doi: 10.1016/j.ahj.2020.07.004. Epub 2020 Jul 14.
9
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.白细胞介素-1受体拮抗剂rilonacept治疗复发性心包炎的3期试验
N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16.
10
A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option.复发性心包炎治疗概述及利纳西普作为一种新的治疗选择的潜力。
Am J Cardiovasc Drugs. 2022 Jan;22(1):27-33. doi: 10.1007/s40256-021-00481-x. Epub 2021 May 19.
引用本文的文献
1
Real-world data and Mendelian randomization analysis in assessing adverse reactions of rilonacept.评估瑞洛昔普不良反应的真实世界数据和孟德尔随机化分析
Int J Clin Pharm. 2025 Jul 2. doi: 10.1007/s11096-025-01932-0.
本文引用的文献
1
Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.长期用利纳西普降低持续性心包炎复发风险。
J Am Heart Assoc. 2024 Mar 19;13(6):e032516. doi: 10.1161/JAHA.123.032516. Epub 2024 Mar 12.
2
A meta analysis on the utility of Anakinra in severe COVID-19 disease.一项关于阿那白滞素在严重 COVID-19 疾病中的效用的荟萃分析。
Cytokine. 2023 Sep;169:156311. doi: 10.1016/j.cyto.2023.156311. Epub 2023 Aug 1.
3
US Database Study of Clinical Burden and Unmet Need in Recurrent Pericarditis.美国数据库研究复发性心包炎的临床负担和未满足的需求。
J Am Heart Assoc. 2021 Aug 3;10(15):e018950. doi: 10.1161/JAHA.120.018950. Epub 2021 Jul 21.
Zotero 插件